-
First-trimester biochemical markers of aneuploidy and the prediction of small-for-gestational age fetuses.
Spencer K, Cowans NJ, Avgidou K, Molina F, Nicolaides KH.
Ultrasound Obstet Gynecol 2008;31:15-9. -
First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of preterm or early preterm delivery.
Spencer K, Cowans NJ, Molina F, Kagan KO, Nicolaides KH.
Obstet Gynecol 2008;31:147-52. -
Low levels of maternal serum PAPP-A in the first trimester and the risk of pre-eclampsia.
Spencer K, Cowans NJ, Nicolaides KH.
Prenat Diagn 2008;28:7-10. -
Screening for adverse pregnancy outcome by ductus venosus Doppler at 11-13+6 weeks of gestation.
Maiz N, Valencia C, Emmanuel EE, Staboulidou I, Nicolaides KH.
Obstet Gynecol 2008;112:598-605. -
Screening for trisomy 18 by maternal age, fetal nuchal translucency, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Kagan KO, Wright D, Maiz N, Pandeva I, Nicolaides KH.
Ultrasound Obstet Gynecol 2008;32:488-92. -
Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Kagan KO, Wright D, Baker A, Sahota D, Nicolaides KH.
Ultrasound Obstet Gynecol 2008;31:618-24. -
First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics.
Kagan KO, Wright D, Spencer K, Molina FS, Nicolaides KH.
Ultrasound Obstet Gynecol 2008;31:493-50. -
Screening for triploidy by the risk algorithms for trisomies 21, 18 and 13 at 11 weeks to 13 weeks and 6 days of gestation.
Kagan KO, Anderson JM, Anwandter G, Nekrasova K, Nicolaides KH.
Prenat Diagn 2008;28:1209-13. -
Screening for trisomies 21, 18 and 13 by maternal age, fetal nuchal translucency, fetal heart rate, free beta-hCG and pregnancy-associated plasma protein-A.
Kagan KO, Wright D, Valencia C, Maiz N, Nicolaides KH.
Hum Reprod 2008;23:1968-75. -
First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of impending fetal death.
Spencer K, Cowans NJ, Avgidou K, Nicolaides KH.
Ultrasound Obstet Gynecol 2006;28:637-43. -
Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
Falcon O, Auer M, Gerovassili A, Spencer K, Nicolaides KH.
Ultrasound Obstet Gynecol 2006;27:151-5. -
A first trimester trisomy 13/trisomy 18 risk algorithm combining fetal nuchal translucency thickness, maternal serum free beta-hCG and PAPP-A.
Spencer K, Nicolaides KH.
Prenat Diagn 2002;22:877-9. -
One-stop clinic for assessment of risk of chromosomal defects at 12 weeks of gestation.
Nicolaides KH, Bindra R, Heath V, Cicero S.
J Matern Fetal Neonatal Med 2002;12:9-18. -
Fetal nasal bone length in chromosomally normal and abnormal fetuses at 11-14 weeks of gestation.
Cicero S, Bindra R, Rembouskos G, Tripsanas C, Nicolaides KH.
J Matern Fetal Neonatal Med 2002;11:400-2. -
One-stop clinic for assessment of risk for trisomy 21 at 11-14 weeks: a prospective study of 15 030 pregnancies.
Bindra R, Heath V, Liao A, Spencer K, Nicolaides KH.
Ultrasound Obstet Gynecol 2002;20:219-25.